- Home
- / GlycoNex
GlycoNex
Stock Price
NT$26.5
2024-10-29
Market Capitalization
NT$2.8 B
2024-10-29
Revenue
NT$37.9 M
FY, 2025
GlycoNex Summary
Company Summary
- Overview
- GlycoNex (台灣醣聯生技醫藥股) is a company developing cancer drugs utilizing glycosphingolipid antigen and human monoclonal antibody technologies. Its platform enables glycosphingolipid antigen production and identification, monoclonal antibody production, cancer drug screening, as well as pharmacology and pharmacokinetics assessment.
- Type
- Public
- Status
- Active
- Founded
- 2001
- HQ
- TW | view all locations
- Website
- http://www.glyconex.com.tw/
- Cybersecurity rating
- ESG rating
Table of Contents
LocationsView all
1 location detected
New Taipei City HQ
Taiwan
Xintai 5th Rd. Under-bridge, Xizhi District
GlycoNex Financials
Summary Financials
- Revenue (FY, 2025)
- NT$37.9M
- Gross profit (FY, 2025)
- NT$36.7M
- Net income (FY, 2025)
- (NT$235.2M)
- Cash (FY, 2025)
- NT$467.7M
- EBIT (FY, 2025)
- (NT$236.4M)
- Enterprise value
- $2.8B
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026